Anti-Human CD3 x DLL3 (Tarlatamab)

This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Recombinant biosimilar antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Tarlatamab. Tarlatamab targets CD3 on T-cells and DLL3 on tumor cells.

Anti-Human CD3 x DLL3 is a bispecific T-cell engager (BiTE) designed to target CD3 on T- cells and Delta-like ligand 3 (DLL3) on tumor cells. DLL3 is highly expressed in small cell lung cancer (SCLC) and other neuroendocrine tumors, making it an attractive target for immunotherapy. By redirecting T-cells to attack DLL3-expressing tumor cells, this bispecific antibody offers a novel treatment approach for SCLC, a disease known for its poor prognosis and limited therapeutic options. Preclinical studies have demonstrated that DLL3/CD3 bispecific antibodies can induce potent, DLL3-dependent T-cell-mediated lysis of tumor cells, recruit T-cells into non-inflamed tumor tissues, and lead to tumor regression in animal models. While specific efficacy data for this antibody are not provided, BiTE antibodies have generally shown high potency, with some studies indicating efficacy at sub-picomolar concentrations.^1-3.

AMG 757, also known as Tarlatamab, is a promising example of a bispecific T-cell engager targeting DLL3 and CD3 for SCLC treatment. Studies have shown that AMG 757 induces potent tumor lysis and T-cell activation, resulting in significant tumor regression and even complete responses in preclinical models. Clinical trials have reported manageable safety profiles with encouraging response durability, including objective response rates of 23.4% to 40% and disease control rates of 51.4%. Notably, AMG 757 has demonstrated antitumor activity with durable responses and promising survival outcomes in patients with previously treated SCLC, making it a viable option for targeting DLL3-expressing tumors^4-6.

The distribution of Anti-Human CD23 x DLL3 in the body includes the blood and lymphatic tissues, where it can effectively engage with both T-cells and tumor cells.

CD3ε: TCR
DLL3: Notch-1

CD3ε: P07766
DLL3: Q9NYJ7

1. Lin S, Zhang Y, Yao J, et al. J Transl Med. 2024;22(1):766.
2. Hipp S, Voynov V, Drobits-Handl B, et al. Clin Cancer Res. 2020;26(19):5258-5268.
3. Dreier T, Lorenczewski G, Brandl C, et al. Int J Cancer. 2002;100(6):690-697.
4. Paz-Ares L, Champiat S, Lai WV, et al. J Clin Oncol. 2023;41(16):2893-2903.
5. Giffin MJ, Cooke K, Lobenhofer EK, et al. Clin Cancer Res. 2021;27(5):1526-1537.
6. Ahn MJ, Cho BC, Felip E, et al. N Engl J Med. 2023;389(22):2063-2075.
7. Tarlatamab (AMG-757) | anti-DLL3/CD3 BiTE antibody | MedChemExpress. MedchemExpress.com. Accessed September 30, 2024. https://www.medchemexpress.com/tarlatamab.html